Anti-neutrophil antibodies (anti-MPO-ANCAs) are associated with poor prognosis in breast cancer patients |
| |
| Affiliation: | 1. Laboratory of Tumor Biology, State University of West Paraná (Unioeste), Francisco Beltrão, Paraná, Brazil;2. Federal University of Rio de Janeiro, Brazil;3. Post-graduation Program of Health-Applied Sciences, State University of West Paraná (Unioeste), Francisco Beltrão, Paraná, Brazil;4. Francisco Beltrão Cancer Hospital (Ceonc), Francisco Beltrão, Paraná, Brazil;1. Master’s Program in Science and Health, Federal University of Piauí, Brazil;2. Maringá State University, Center of Biological Sciences, Department of Basic Health Sciences (DBS), Maringá, Paraná, Brazil;3. Federal University of Piauí, Chemistry Department, Teresina, Piauí, Brazil;4. Federal University of Piauí, Laboratory of Immunogenetics and Molecular Biology (LIB), Teresina, Piauí, Brazil;5. PIBIC – CNPq – Federal University of Piauí, Laboratory of Immunogenetics and Molecular Biology, Teresina, Piauí, Brazil;6. PIBITI – CNPq – Federal University of Piauí, Teresina, Piauí, Brazil;1. Department of Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;2. National Clinical Research Center for Cancer, China;3. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China;4. Tianjin Clinical Research Center for Cancer, China;5. Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;6. Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;7. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;1. Department of Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China;2. Department of Cardiovascular Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China;1. Fundação Oswaldo Cruz-Fiocruz, Instituto Aggeu Magalhães, Laboratório de Imunoparasitologia, Recife, PE, Brazil;2. Universidade Federal de Pernambuco, Laboratório de Imunopatologia Keizo Asami, Laboratório de Virologia, Recife, PE, Brazil;3. Fundação Altino Ventura - FAV, Recife, PE, Brazil;4. Ambulatório de Doença de Chagas e Insuficiência Cardíaca do Pronto Socorro Cardiológico de Pernambuco, Recife, PE, Brazil;5. Fundação Oswaldo Cruz- Fiocruz, Instituto Oswaldo Cruz, Laboratório de Biologia das Interações, Rio de Janeiro, RJ, Brazil;1. Department of Immunology and Microbiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA;2. Division of Rheumatology, Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA |
| |
| Abstract: | Anti-neutrophil antibodies are capable of activating neutrophils in sterile environments, releasing extracellular traps containing myeloperoxidase (MPO) and anti-MPO antibodies (MPO-ANCAs or anti-MPO-ANCAs), which have been implicated in the pathogenesis of several diseases. The present study evaluated systemic and tumor tissue levels of anti-MPO-ANCAs breast cancer patients, and its relation to clinicopathological characteristics. Anti-MPO-ANCAs were measured in serum and tissue samples of 150 patients by enzyme-linked immunoassay. Samples were pooled according to clinicopathological characteristics of patients. Higher anti-MPO-ANCAs levels were detected in groups presenting negative clinicopathological characteristics, such as high histological grade tumors and risk factors such as body mass index, menopausal status and early onset at diagnosis. The present data highlights anti-MPO-ANCAs as associated to poor prognosis in breast cancer, a role beyond its actually discussed role in autoimmunity and vasculitis. |
| |
| Keywords: | Antineutrophil antibodies Myeloperoxidase Breast cancer Prognosis Anti-MPO-ANCAs |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
